BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 11235821)

  • 1. Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.
    Clark TE; Edom N; Larson J; Lindsey LJ
    Drug Saf; 2001; 24(2):87-117. PubMed ID: 11235821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide: a review of approved and investigational uses.
    Matthews SJ; McCoy C
    Clin Ther; 2003 Feb; 25(2):342-95. PubMed ID: 12749503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Thalidomide: new uses for an old drug].
    Wu KL; Sonneveld P
    Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1438-41. PubMed ID: 12190008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of thalidomide in the management of erythema nodosum leprosum.
    Walker SL; Waters MF; Lockwood DN
    Lepr Rev; 2007 Sep; 78(3):197-215. PubMed ID: 18035771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide in the treatment of erythema nodosum leprosum (ENL) in an outpatient setting: A five-year retrospective analysis from a leprosy referral centre in India.
    Upputuri B; Pallapati MS; Tarwater P; Srikantam A
    PLoS Negl Trop Dis; 2020 Oct; 14(10):e0008678. PubMed ID: 33035210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dependent thalidomide induced bradycardia in young erythema nodosum leprosum patient.
    Thangaraju P; Venkatesan S; Sivashanmugam E; Showkath Ali MK
    Indian J Pharmacol; 2019; 51(1):72-74. PubMed ID: 31031470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide: a remarkable comeback.
    Jacobson JM
    Expert Opin Pharmacother; 2000 May; 1(4):849-63. PubMed ID: 11249521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Japanese guideline on thalidomide usage in the management of erythema nodosum leprosum].
    Ishii N; Ishida Y; Okano Y; Ozaki M; Gidoh M; Kumano K; Goto M; Nogami R; Hatano K; Yamada A; Yotsu RR
    Nihon Hansenbyo Gakkai Zasshi; 2011 Sep; 80(3):275-85. PubMed ID: 21941834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide: current and potential clinical applications.
    Calabrese L; Fleischer AB
    Am J Med; 2000 Apr; 108(6):487-95. PubMed ID: 10781782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe form of type 2 reaction in patients of Hansen's disease after withdrawal of thalidomide: case reports.
    Rattan R; Shanker V; Tegta GR; Verma GK
    Indian J Lepr; 2009; 81(4):199-203. PubMed ID: 20704076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature.
    Fabi SG; Hill C; Witherspoon JN; Boone SL; West DP
    J Drugs Dermatol; 2009 Aug; 8(8):765-9. PubMed ID: 19663116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide for erythema nodosum leprosum and other applications.
    Okafor MC
    Pharmacotherapy; 2003 Apr; 23(4):481-93. PubMed ID: 12680478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dermatologic and nondermatologic uses of thalidomide.
    Nasca MR; Micali G; Cheigh NH; West LE; West DP
    Ann Pharmacother; 2003 Sep; 37(9):1307-20. PubMed ID: 12921515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The return of thalidomide: can birth defects be prevented?
    Lary JM; Daniel KL; Erickson JD; Roberts HE; Moore CA
    Drug Saf; 1999 Sep; 21(3):161-9. PubMed ID: 10487395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thalidomide used by patients with erythema nodosum leprosum].
    Valente Mdo S; Vieira JL
    Rev Soc Bras Med Trop; 2010; 43(2):201-4. PubMed ID: 20464154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of CD64 on Circulating Neutrophils Favoring Systemic Inflammatory Status in Erythema Nodosum Leprosum.
    Schmitz V; Prata RB; Barbosa MG; Mendes MA; Brandão SS; Amadeu TP; Rodrigues LS; Ferreira H; Costa Fda M; Dos Santos JB; Pacheco Fdos S; Machado Ade M; Nery JA; Hacker Mde A; Sales AM; Pinheiro RO; Sarno EN
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004955. PubMed ID: 27556927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
    de Carsalade GY; Achirafi A; Flageul B
    Acta Leprol; 2003; 12(3):117-22. PubMed ID: 15040702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide levels in patients with erythema nodosum leprosum.
    Vieira JL; Valente Mdo S
    Ther Drug Monit; 2009 Oct; 31(5):602-3. PubMed ID: 19704404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum.
    Villahermosa LG; Fajardo TT; Abalos RM; Balagon MV; Tan EV; Cellona RV; Palmer JP; Wittes J; Thomas SD; Kook KA; Walsh GP; Walsh DS
    Am J Trop Med Hyg; 2005 May; 72(5):518-26. PubMed ID: 15891124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep vein thrombosis: a rare complication of thalidomide therapy in recurrent erythema nodosum leprosum.
    Sharma NL; Sharma V; Shanker V; Mahajan VK; Sarin S
    Int J Lepr Other Mycobact Dis; 2004 Dec; 72(4):483-5. PubMed ID: 15755204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.